Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360486 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-05-06
Summary
This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.
Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
- BIOLOGICAL
-
Anti-Sars-CoV-2 Convalescent Plasma
Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma
Sponsors & Collaborators
-
U.S. Army Medical Research and Development Command
lead FED
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
- Afghanistan
- Djibouti
- Germany
- Guam
- Iraq
- Japan
- Kuwait
Study Locations
More Related Trials
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
NCT04392232 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)
NCT04390178 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
NCT04474340 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
NCT04438057 ·Status: COMPLETED ·Phase: PHASE2
-
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
NCT04445207 ·Status: NO_LONGER_AVAILABLE
-
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992 ·Status: COMPLETED ·Phase: PHASE1
-
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
NCT04364737 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Convalescent Plasma
NCT04340050 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Convalescent Plasma for COVID-19
NCT04365439 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
NCT04354831 ·Status: COMPLETED ·Phase: PHASE2
-
CoVID-19 Plasma in Treatment of COVID-19 Patients
NCT04355897 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
NCT04502472 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease
NCT04542967 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
NCT04373460 ·Status: COMPLETED ·Phase: PHASE2
-
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients
NCT04420988 ·Status: NO_LONGER_AVAILABLE
-
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
NCT04513158 ·Status: TERMINATED ·Phase: PHASE2
-
Convalescent Plasma as a Possible Treatment for COVID-19
NCT04442191 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
NCT04292340 ·Status: UNKNOWN
-
COVID-19 Convalescent Plasma for Mechanically Ventilated Population
NCT04388527 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19
NCT04433910 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma Therapy - Zurich Protocol
NCT04869072 ·Status: COMPLETED ·Phase: PHASE1
-
Plasma Therapy of COVID-19 in Severely Ill Patients
NCT04359810 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
NCT04397757 ·Status: COMPLETED ·Phase: PHASE1
-
Convalescent Plasma for Treatment of COVID-19
NCT04649879 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Convalescent Plasma in the Treatment of Covid-19
NCT04600440 ·Status: UNKNOWN ·Phase: NA